TG Therapeutics CEO to Speak at H.C. Wainwright Conference
News related to:TG Therapeutics, Inc · 1 min read
NEW YORK, Sept. 10, 2026 /CourierPR/ -- TG Therapeutics, Inc., a biotechnology company focused on the development of novel treatments for B-cell diseases, will be participating in the H.C. Wainwright 28th Annual Global Investment Conference. The company’s CEO, Michael S. Weiss, will participate in a fireside chat on Monday, September 14, 2026, at 12:00pm ET.
The event, which will take place from September 14 to 16, 2026, offers a platform for discussions on the latest advancements and future prospects in the pharmaceutical industry. Weiss, a key figure in TG Therapeutics, will share insights on the company’s pipeline and recent developments, including the FDA approval of BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS).
BRIUMVI® has received approval from the U.S. Food and Drug Administration (FDA) and several regulatory bodies outside the U.S. for treating adult patients with RMS who have active disease defined by clinical or imaging features. This approval underscores the company’s commitment to providing innovative therapies for patients suffering from RMS.
TG Therapeutics, based on its research and development, continues to explore potential new treatments for B-cell diseases. During the conference, Weiss will provide an update on the company’s ongoing efforts and future plans, highlighting the significance of its work in the field of biotechnology.
Attendees of the H.C. Wainwright conference will have the opportunity to access a live webcast of the fireside chat. The session can be viewed on the Events page within the Investors & Media section of TG Therapeutics’ website at ir.tgtherapeutics.com/events. This webcast will provide an important opportunity for investors, analysts, and industry professionals to engage directly with TG Therapeutics and gain a deeper understanding of the company’s strategic direction and future prospects.
The participation of TG Therapeutics in this significant investment conference is expected to attract considerable attention from the pharmaceutical and biotech communities, offering a platform for further discussions and collaborations.